Retatrutide

Extreme Fat loss peptide via bioregulation Retatrutide LY 3437943 is an experimental drug for obesity. It is a triple glucagon hormone receptor agonist GLP 1, GIP, and GCGR receptors . Preclinical and biochemical studies describe receptor activity at GLP 1, GIP, and glucagon receptors. Reports on its development state that it was engineered for activity across these targets. Systematic reviews and meta analyses of randomized controlled trials report that Retatrutide produces substantial reductions in body weight in adults with obesity, with mean percentage weight loss typically between 15 and 24 percent over 48 to 72 weeks, depending on study protocols and populations. Adverse events are most commonly gastrointestinal symptoms such as nausea and diarrhoea with relatively low rates of study discontinuation and infrequent serious adverse events reported during trials. Safety assessments also indicate a low risk of hypoglycaemia and no significant elevation in cardiovascular or hepatic adverse events in non diabetic populations across published studies.